Key result
Short-term administration of antiarrhythmic drugs after catheter ablation for atrial fibrillation reduced early recurrence (OR 0.47; 95% CI 0.34-0.64) but did not prevent late recurrence.
Why the study?
Does short-term administration of antiarrhythmic drugs reduce the recurrence of atrial fibrillation in patients after catheter ablation?
Meta-Analysis (n=814)
Does short-term administration of antiarrhythmic drugs reduce the recurrence of atrial fibrillation in patients after catheter ablation?
Effect estimate: OR 0.47 (95% CI 0.34-0.64)
Absolute Event Rate: 25.3% vs 39.8%
Short-term administration of antiarrhythmic drugs after catheter ablation for atrial fibrillation reduces early but not late recurrence of atrial tachyarrhythmias.
Reduces early AF recurrence after ablation but not late; confirms targeted short-term use without long-term benefit.
BACKGROUND: Whether the short-term administration of antiarrhythmic drugs (AADs) to maintain sinus rhythm following catheter ablation (CA) for atrial fibrillation (AF) can prevent the recurrence of AF is still a matter of debate. We searched the PubMed database and the Cochrane Library, and compiled a list of retrieved articles. We included only randomised controlled trials(RCTs) that compared any AADs against control (placebo or no treatment) or other AADs following CA for AF. Statistical analysis of the odds ratio (OR) and corresponding 95% confidence interval (CI) were used to determine the overall effect of both outcomes. The Mantel-Haenszel method was used to pool data of the outcomes of AF recurrence into fixed effect model meta-analyses. AIMS: We performed a systematic review to determine the effectiveness of short-term treatment with AADs on the recurrence of AF after CA. RESULTS: Six RCTs were included in this study, with a total of 814 patients. Post-procedural temporary administration of AADs in patients after CA for AF reduced the early recurrence of AF (antiarrhythmic drug 103 patients [25.3%], control 162 patients [39.8%]; OR 0.47 [95% CI 0.34-0.64]; χ(2) = 3.77; P = 0.58; I(2) = 0%). No significant difference in patients after CA for AF in the late recurrence of AF (antiarrhythmic drug 148 patients [36.5%], control 171 patients [42.5%]; OR 0.77 [95% CI 0.57-1.03]; χ(2) = 3.15; P = 0.68; I(2) = 0%). The heterogeneity was zero in both analyses. CONCLUSION: Although the continued administration of AADs after CA for AF can decrease early atrial tachycardias (ATa), this treatment does not prevent late ATa.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2015) conducted a meta-analysis in Atrial fibrillation (n=814). Antiarrhythmic drugs (AADs) vs. Control (placebo or no treatment) or other AADs was evaluated on Early recurrence of atrial fibrillation (OR 0.47, 95% CI 0.34-0.64). Short-term administration of antiarrhythmic drugs after catheter ablation for atrial fibrillation reduced early recurrence (OR 0.47; 95% CI 0.34-0.64) but did not prevent late recurrence.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: